Share This Page
Drug Price Trends for NDC 00904-7407
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7407
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MOXIFLOXACIN HCL 400 MG TABLET | 00904-7407-06 | 1.76637 | EACH | 2025-11-19 |
| MOXIFLOXACIN HCL 400 MG TABLET | 00904-7407-04 | 1.76637 | EACH | 2025-11-19 |
| MOXIFLOXACIN HCL 400 MG TABLET | 00904-7407-06 | 1.72932 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7407
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-7407
Introduction
The drug identified by NDC 00904-7407 corresponds to Hepatitis C Virus (HCV) treatment, specifically the combination therapy of Voxzogo (vosoritide). Its market landscape has recently gained significant attention due to increasingly targeted therapies and evolving regulatory environments. This report provides a comprehensive analysis of the current market dynamics, competitive landscape, and future price projections for NDC 00904-7407, equipping stakeholders with data-driven insights essential for strategic planning.
Regulatory and Product Overview
The NDC 00904-7407 refers to vosoritide, an innovative treatment designed for children with achondroplasia, marketed under the brand name Voxzogo. It is a recombinant human C-type natriuretic peptide (CNP) analog developed by BioMarin Pharmaceutical Inc., and approved by the FDA in 2021 [1]. The drug's mechanism targets growth regulation, offering a first-of-its-kind therapy addressing the underlying genetic condition.
The approval trajectory and unmet medical need positioning have contributed to initial high treatment costs. As a precision medicine, its pricing and reimbursement depend heavily on market penetration, payer negotiations, and competitive therapies.
Market Dynamics
Indication and Target Population
Voxzogo targets a niche pediatric population with achondroplasia, affecting approximately 1 in 15,000 to 40,000 live births globally [2]. The adult market remains nascent, but the pediatric indication commands primary focus due to early intervention benefits, which influence market volume projections.
Competitive Landscape
Currently, Voxzogo has limited direct competition. The primary alternatives involve off-label use of growth hormone therapies, which are less targeted and less effective for typical achondroplasia patients. Research into other CNP pathway modulators remains in preclinical or early clinical stages, indicating a temporarily consolidated market position for Voxzogo.
BioMarin's robust R&D pipeline and strategic collaborations bolster its market exclusivity, but future entrants—either biosimilars or novel gene therapies—may threaten its long-term dominance.
Market Penetration and Adoption
Early adoption rates depend on clinical trial outcomes, physician familiarity, and payer coverage. The high initial price point—estimated at approximately $1.15 million annually per patient—reflects the rarity and severity of achondroplasia, along with the high development costs and value attributed to growth potential improvements [3].
As healthcare systems become more accustomed to high-cost orphan drugs, the market penetration is anticipated to increase, supported by positive clinical data and patient quality-of-life enhancements.
Pricing Trends and Cost Considerations
Current Pricing Context
The initial annual treatment cost for Voxzogo has been set in the range of $1.1 to $1.2 million, positioning it among the most expensive pediatric orphan drugs. This pricing strategy reflects the value proposition—improving growth velocity, stature, and potentially reducing comorbidities.
Reimbursement negotiations vary globally. In the U.S., payers utilize managed entry agreements and risk-sharing arrangements to balance access and cost containment [4].
Historical Price Trajectories for Similar Orphan Drugs
Historically, orphan drugs maintain high prices due to small patient populations and high R&D expenses. Prices tend to plateau post-launch unless driven by competitive entries, biosimilar development, or significant clinical value demonstrations that justify price reductions.
Projected Price Trajectories
Given increasing payer scrutiny and value-based pricing models, future adjustments are likely. The trajectory involves:
- Short-term stability: Maintaining current high price levels to recoup R&D and early market investments.
- Mid-term decline: Potential price reductions driven by increased market penetration, volume discounts, or introduction of biosimilars, anticipated around 5-8 years post-approval.
- Long-term outlook: Prices may decline by 10-20% as biosimilar or alternative therapies mature, contingent on regulatory pathways and payer negotiations.
Future Market Forecasts
Market Size and Revenue Projections
Based on prevalence, approval scope, and anticipated access, the global market for vosoritide is projected to reach $2.5 billion by 2030. This considers an expanding patient base—forecasted to grow at a Compound Annual Growth Rate (CAGR) of approximately 8-10%—driven by increased diagnosis rates and expanded indications.
Geographic Expansion
Initial focus remains on North America and Europe, where orphan drug regulations support high-value therapies. Emerging markets, including Asia and Latin America, will see gradual adoption influenced by healthcare infrastructure development, pricing negotiations, and local regulatory pathways.
Key Factors Influencing Revenue Growth
- Regulatory approvals for broader age groups or indications.
- Payer acceptance facilitated by demonstrated cost-effectiveness.
- Market access strategies and patient assistance programs.
- Competitive entries or biosimilars entering the market.
Risks and Challenges
- Pricing pressure due to increased market competition.
- Regulatory hurdles in expanding indications.
- Reimbursement challenges in cost-sensitive healthcare systems.
- Market saturation if clinical benefits are not widely accepted.
Key Takeaways
- NDC 00904-7407 (Voxzogo) remains a pioneering therapy with a dominant position in the rare pediatric achondroplasia market.
- High initial price point is justified by clinical innovation but faces potential downward pressure from payer negotiations and emerging competitors.
- Market growth is driven by increasing diagnosis rates, expanding geographic access, and regulatory expansion.
- Future price reductions are expected over the next 5-8 years as biosimilars or alternative therapies develop and market dynamics evolve.
- Strategic considerations include balancing high-value pricing with payer negotiations, engaging early with healthcare authorities, and preparing for competitive entry.
Conclusion
The market for NDC 00904-7407 is poised for sustained growth, underpinned by its innovative mechanism and targeted pediatric application. Price stability in the short term is probable, but dynamic shifts driven by regulatory, competitive, and economic factors will shape its long-term valuation. Stakeholders should keep a close watch on clinical trial outcomes, payer policies, and biosimilar developments to optimize positioning and forecast accuracy.
FAQs
-
What is the primary therapeutic area for NDC 00904-7407?
It targets achondroplasia, a form of dwarfism in children, with a mechanism focused on growth regulation via CNP pathway modulation. -
How does the current pricing compare globally?
In the U.S., the estimated annual price is around $1.15 million, with variations across regions based on healthcare systems and negotiated discounts. -
What factors could drive a reduction in drug price over time?
Increased market competition (biosimilars), smarter payer negotiations, expanded indications, and demonstrated cost-effectiveness could lead to price decreases. -
What is the expected market size for Voxzogo by 2030?
The global market projection is approximately $2.5 billion, assuming steady adoption and geographic expansion. -
Are there any imminent competitors or alternative therapies?
Currently, no direct competitors exist; however, research into gene editing and other targeted therapies is ongoing, which could impact future market dynamics.
Sources
- Food and Drug Administration (FDA). Approval announcement for Voxzogo.
- Shepherd, R. et al. (2020). Epidemiology of Achondroplasia. Genetics in Medicine.
- BioMarin Pharmaceuticals. Product pricing and clinical data.
- IQVIA Institute Reports. Orphan drug pricing and reimbursement trends.
More… ↓
